Details of the Drug

General Information of Drug (ID: DM1KL69)

Drug Name

IGV-001

Indication

Disease Entry	ICD 11	Status	REF
Glioblastoma	2A00	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Vaccine

Cross-matching ID

References

1	ClinicalTrials.gov (NCT04485949) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma. U.S.National Institutes of Health.